Utah Medical Products, Inc.

Utah Medical Products, Inc.

UTMDNYSE / NASDAQHealthcareSmall cap

$69.49-$1.47 (-2.1%)

Last close · Data as of Nov 20, 2026

Market cap
$216.5M
P/E
19.2x
EV / EBITDA
9.1x
Revenue
$38.5M
Net margin
29.3%
ROCE
9.6%

+29.2% over the last year

Utah Medical Products, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-7.4%
3M
-2.7%
6M
+8.3%
1Y
+29.2%
5Y
-39.9%

52-week range

Day change -$1.47 (-2.1%) from $71 to $69 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in UTMD, bought on each weekday since 2021.

News & filings

What Utah Medical Products filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthFree cash flow was 37.2% of revenue in fiscal 2025.

Concerns (1)

  • Return on equity of 9.5%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.

Read moreShow less

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Sector
Healthcare
Shares outstanding
3.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$216.5M
P/E
19.2x
P/B
1.8x
EV / EBITDA
9.1x
EV / Sales
3.4x
P/S
5.6x
52-week high
$76.66
52-week low
$53.80

Profitability

Operating margin
29.6%
Net margin
29.3%
EBITDA margin
37.4%
ROE
9.5%
ROCE
9.6%
ROIC
27.0%
ROA
9.2%
Asset turnover
0.31

Growth

Revenue
$38.5M
Revenue growth, 1Y
-5.8%
Revenue CAGR, 3Y
-9.7%
Net profit growth, 1Y
-18.7%
Free cash flow
$14.3M

Solvency

Current ratio
37.59
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
1.30
Cash / Market cap
39.6%

Where the revenue went

Of every $100 of FY2025 revenue, $29 was left as net income.

Utah Medical Products, Inc. income statement flow, FY2025
Utah Medical Products, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$16.5M
RevenueGross profit$22.0M
Gross profitResearch and development$670.0k
Gross profitSelling, general and administrative$9.9M
Gross profitOther operating expenses$0.00
Gross profitOperating income$11.4M
Operating incomePretax income$11.4M
Interest and other incomePretax income$2.7M
Pretax incomeTax and other$2.8M
Pretax incomeNet income$11.3M

Revenue and net profit

Revenue fell 5.8% in FY2025; net profit is the dashed line.

Utah Medical Products, Inc. revenue and net profit by fiscal year
Utah Medical Products, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$52.3M$16.5M
FY2023$50.2M$16.6M
FY2024$40.9M$13.9M
FY2025$38.5M$11.3M

Cash flows

FY2025: $14.7M from operations, $14.3M free after investment (dashed).

Utah Medical Products, Inc. operating and free cash flow by fiscal year
Utah Medical Products, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$21.1M$20.3M
FY2023$22.3M$21.6M
FY2024$14.8M$14.6M
FY2025$14.7M$14.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$38.5M-5.8%1Y
EBITDA
$14.4M-12.3%1Y
Net profit
$11.3M-18.7%1Y
Cash from operations
$14.7M-0.9%1Y
Free cash flow
$14.3M-1.9%1Y
Revenue CAGR, 3Y
-9.7%
Net profit CAGR, 3Y
-11.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$38.5M$14.4M$11.3M$14.3M9.5%-5.8%-18.7%

Monthly returns

Month-by-month returns of UTMD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$122.5M
Liabilities$3.3M
Equity$119.3M
Paid-in capital$0.00
Retained earnings$128.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; UTMD highlighted.

P/E against peers

UTMD trades at 19.2x earnings against a peer median of -2.7x.

  1. Utah Medical Products, Inc. (this company)19.2x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Fulcrum Therapeutics, Inc., Inhibikase Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Utah Medical Products, Inc.UTMDthis company$216.5M19.2x1.8x9.5%9.1x
Fulcrum Therapeutics, Inc.FULC$224.6M—0.6x-21.5%—
Foghorn Therapeutics Inc.FHTX$219.6M-3.0x-2.0x68.5%-2.3x
Inhibikase Therapeutics, Inc.IKT$219.2M-4.5x1.3x-27.9%-1.5x
Voyager Therapeutics, Inc.VYGR$218.7M-1.8x1.1x-61.1%-1.5x
Pro-Dex, Inc.PDEX$213.9M23.8x5.8x24.5%16.3x
Keros Therapeutics, Inc.KROS$213.2M2.4x0.7x28.7%-0.8x
RxSight, Inc.RXST$211.1M-5.4x0.8x-14.1%-5.7x
Atrium Therapeutics, Inc.RNA$210.4M-2.7x1.0x-37.0%0.7x
Peer median—-2.7x0.9x-17.8%-1.5x

Year-to-date ROI

UTMD since 1 January, against earlier years.

Historical volatility

UTMD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Utah Medical Products, Inc. operating margin by fiscal year
Utah Medical Products, Inc. operating margin by fiscal year
DateOperating margin
FY202237.9%
FY202333.4%
FY202433.2%
FY202529.6%
LineFY2025
Cost of revenueCost Of Revenue$16.5M
Gross profitGross Profit$22.0M
Operating expensesOperating Expense$10.6M
Research and developmentResearch And Development$670.0k
Total expensesTotal Expenses$27.1M
Pretax incomePretax Income$14.1M

Learn while you research

Academy chapters picked for Utah Medical Products, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →